April 30 (Reuters) - Trillium Therapeutics Inc TRIL.TO :
* TRILLIUM ANNOUNCES MANAGEMENT AND BOARD CHANGES AND PROVIDES CORPORATE UPDATE
* TRILLIUM THERAPEUTICS INC - IN INTERIM, BOARD OF DIRECTORS HAS APPOINTED ROBERT L. KIRKMAN, M.D., CURRENT CHAIRMAN OF BOARD, AS EXECUTIVE CHAIRMAN
* TRILLIUM THERAPEUTICS INC - BOARD OF DIRECTORS HAS APPOINTED A COMMITTEE TO LEAD A SEARCH FOR TRILLIUM'S NEXT CHIEF EXECUTIVE OFFICER.
* TRILLIUM THERAPEUTICS INC - NICLAS STIERNHOLM HAS INFORMED BOARD OF DIRECTORS OF HIS RESIGNATION AS PRESIDENT & CHIEF EXECUTIVE OFFICER OF COMPANY
* TRILLIUM THERAPEUTICS INC - NICLAS STIERNHOLM INFORMED BOARD OF DIRECTORS OF HIS RESIGNATION AS PRESIDENT & CHIEF EXECUTIVE OFFICER
* TRILLIUM THERAPEUTICS - TRIAL OF INTRATUMORAL INJECTION OF TTI-621 CONTINUES WITH ADDITIONAL DATA EXPECTED BY YEAR-END 2019
* TRILLIUM THERAPEUTICS - TO SEEK FDA GUIDANCE IN MID-2019 ON A PROPOSED PIVOTAL TRIAL OF INTRATUMORAL TTI-621 IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA